Research ExplorerPublicationsImmuntherapie des HNSCC: Quo vadis?

Immuntherapie des HNSCC: Quo vadis?

Standard

Immuntherapie des HNSCC: Quo vadis? / Döscher, J; Busch, C-J; Schuler, P J; Laban, S.

In: HNO, Vol. 64, No. 10, 10.2016, p. 700-7.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Döscher, J, Busch, C-J, Schuler, PJ & Laban, S 2016, 'Immuntherapie des HNSCC: Quo vadis?', HNO, vol. 64, no. 10, pp. 700-7. https://doi.org/10.1007/s00106-016-0241-8

APA

Döscher, J., Busch, C-J., Schuler, P. J., & Laban, S. (2016). Immuntherapie des HNSCC: Quo vadis? HNO, 64(10), 700-7. https://doi.org/10.1007/s00106-016-0241-8

Vancouver

Döscher J, Busch C-J, Schuler PJ, Laban S. Immuntherapie des HNSCC: Quo vadis? HNO. 2016 Oct;64(10):700-7. https://doi.org/10.1007/s00106-016-0241-8

Bibtex

@article{ec5b02d79ff341bc92cd63ab825ce50a,
title = "Immuntherapie des HNSCC: Quo vadis?",
abstract = "BACKGROUND: Immunotherapy remains a hot topic with an endless stream of new upcoming clinical trials. The results of studies to date are promising for second-line palliative treatment of head and neck squamous cell carcinoma (HNSCC). The next step is testing these strategies in randomized trials for first-line and curative treatment in an adjuvant, neoadjuvant, and primarily nonsurgical setting. So far, established biomarkers have not proven reliable enough to predict response rates precisely.OBJECTIVES: On occasion of the annual meeting of the American Society of Clinical Oncology (ASCO), we aimed to invesitage the future of immunotherapies.METHODS: We collected the most promising upcoming studies alongside current research in the field of biomarkers with a view to interesting new immunotherapeutic strategies.RESULTS: The search for appropriate biomarkers in particular seems to be a central research objective in the short term. There is a broad range of new agents that will be tested in clinical trials as well as the combination of immunotherapy with chemo- and chemoradiotherapy or other immune-modulating drugs.CONCLUSION: The real challenge will be to find the most fitting therapy for each patient out of a large panel of available regimens. Therefore, it is most important to find a set of reliable biomarkers that together could predict treatment response.",
keywords = "English Abstract, Journal Article",
author = "J D{\"o}scher and C-J Busch and Schuler, {P J} and S Laban",
year = "2016",
month = oct,
doi = "10.1007/s00106-016-0241-8",
language = "Deutsch",
volume = "64",
pages = "700--7",
journal = "HNO",
issn = "0017-6192",
publisher = "Springer",
number = "10",

}

RIS

TY - JOUR

T1 - Immuntherapie des HNSCC: Quo vadis?

AU - Döscher, J

AU - Busch, C-J

AU - Schuler, P J

AU - Laban, S

PY - 2016/10

Y1 - 2016/10

N2 - BACKGROUND: Immunotherapy remains a hot topic with an endless stream of new upcoming clinical trials. The results of studies to date are promising for second-line palliative treatment of head and neck squamous cell carcinoma (HNSCC). The next step is testing these strategies in randomized trials for first-line and curative treatment in an adjuvant, neoadjuvant, and primarily nonsurgical setting. So far, established biomarkers have not proven reliable enough to predict response rates precisely.OBJECTIVES: On occasion of the annual meeting of the American Society of Clinical Oncology (ASCO), we aimed to invesitage the future of immunotherapies.METHODS: We collected the most promising upcoming studies alongside current research in the field of biomarkers with a view to interesting new immunotherapeutic strategies.RESULTS: The search for appropriate biomarkers in particular seems to be a central research objective in the short term. There is a broad range of new agents that will be tested in clinical trials as well as the combination of immunotherapy with chemo- and chemoradiotherapy or other immune-modulating drugs.CONCLUSION: The real challenge will be to find the most fitting therapy for each patient out of a large panel of available regimens. Therefore, it is most important to find a set of reliable biomarkers that together could predict treatment response.

AB - BACKGROUND: Immunotherapy remains a hot topic with an endless stream of new upcoming clinical trials. The results of studies to date are promising for second-line palliative treatment of head and neck squamous cell carcinoma (HNSCC). The next step is testing these strategies in randomized trials for first-line and curative treatment in an adjuvant, neoadjuvant, and primarily nonsurgical setting. So far, established biomarkers have not proven reliable enough to predict response rates precisely.OBJECTIVES: On occasion of the annual meeting of the American Society of Clinical Oncology (ASCO), we aimed to invesitage the future of immunotherapies.METHODS: We collected the most promising upcoming studies alongside current research in the field of biomarkers with a view to interesting new immunotherapeutic strategies.RESULTS: The search for appropriate biomarkers in particular seems to be a central research objective in the short term. There is a broad range of new agents that will be tested in clinical trials as well as the combination of immunotherapy with chemo- and chemoradiotherapy or other immune-modulating drugs.CONCLUSION: The real challenge will be to find the most fitting therapy for each patient out of a large panel of available regimens. Therefore, it is most important to find a set of reliable biomarkers that together could predict treatment response.

KW - English Abstract

KW - Journal Article

U2 - 10.1007/s00106-016-0241-8

DO - 10.1007/s00106-016-0241-8

M3 - SCORING: Zeitschriftenaufsatz

C2 - 27624904

VL - 64

SP - 700

EP - 707

JO - HNO

JF - HNO

SN - 0017-6192

IS - 10

ER -